drugset / Trial / NCT02063022

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

NCT02063022

Phase 3 Completed 278 enrolled Italian Sarcoma Group
RandomizedParallel-groupOpen-labelTreatment

Summary

Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment. Both arms will receive an induction treatment followed by surgery (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on the basis of the response to the induction treatment (good or poor)

Timeline

Start
2009-01-22
Primary completion
2022-04-14
Completion
2022-04-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified 4 g
Comparator Cyclophosphamide Other / unclassified 6 g
Comparator Cyclophosphamide Other / unclassified 8.8 g
Comparator Dactinomycin Protein / enzyme biologic 1.5 mg/m2
Comparator Dactinomycin Protein / enzyme biologic 6 mg/m2
Comparator Doxorubicin Other / unclassified 320 mg/m2
Comparator Doxorubicin Other / unclassified 400 mg/m2
Comparator Etoposide Small molecule 1.5 g
Comparator Etoposide Small molecule 1.8 g
Comparator Ifosfamide Small molecule 27 g
Comparator Ifosfamide Small molecule 63 g
Comparator Ifosfamide Small molecule 72 g
Comparator Vincristine Small molecule 12 mg/m2
Comparator Vincristine Small molecule 18 mg/m2
Comparator Busulfan Small molecule
Comparator Melphalan Small molecule

Indications